Why Vista Just Opened a $3 Million Position in Federated Hermes Federated Hermes delivers asset management solutions across equity, fixed income, and money market funds to a diverse client base.
Amazon Aims to Take Over the GLP-1 Market Next. Will That Move the Needle for AMZN Stock? Amazon is expanding into integrated weight-loss care with a scalable healthcare model. Can this expansion meaningfully drive AMZN stock upside?
Hims & Hers Jumps On Its New Eli Lilly-Tied Approach To Obesity Hims & Hers Health can now connect its customers with self-pay prices for Eli Lilly's weight-loss drugs.
Winners And Losers Of Q4: Elanco (NYSE:ELAN) Vs The Rest Of The Pharmaceuticals Stocks Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (
NYSE:ELAN ) and its peers. The pharmaceuti...
Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation. Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance.
Why Merck (MRK) Shares Are Trading Lower Today What Happened? Shares of global pharmaceutical company Merck (
NYSE:MRK ) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Why Did Eli Lilly Stock Drop Today? Can Eli Lilly cure cancer? Maybe -- with a little help.
Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon. Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics fell Tuesday after Amazon announced it would sell weight-loss drugs.
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.
Why Legend Biotech Stock Crushed the Market on Monday Two analysts weighed in positively about the company's future.
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4% Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.
Eli Lilly Goes Atomic—But This Isn't About AI Servers Eli Lilly's nuclear move signals a shift beyond AI, as industrial giants like Nucor and Dow turn to reactors for reliable, 24/7 power.
Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation? Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs.
Eli Lilly (LLY): 3 Reasons We Love This Stock Eli Lilly currently trades at $926.10 and has been a dream stock for shareholders. It’s returned 386% since April 2021, blowing past the S&P 500’s 70.2% gain...
This Drug Stock Has Crushed the S&P 500 Over the Last Decade Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.
Better Long-Term Buy: Eli Lilly or Viking Therapeutics? One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.
